Abstract
Background: Cancer-related inflammation is recognized as a driver for tumor progression and chemokines are important players in both inflammation and the progression of many cancer types. CXC chemokines, especially CXCL8, have been implicated in melanoma growth and metastasis, while less is known for their roles in drug resistance.
Methods: We generated drug-resistant cells by continuous exposure to chemotherapeutic drugs and analyzed the mechanism(s) of therapy resistance in malignant melanoma.
Results: We report chemotherapies induced upregulation of a variety of chemokines in the CXCR1/CXCR2 network by an NF-κB-dependent mechanism. Notably, analysis of the drug-resistant melanoma cell line selected after prolonged exposure to chemotherapeutic drug dacarbazine revealed higher levels of CXCL8 and CXCR2 compared with parent cells as a signature of drug resistance. CXCR2 neutralization markedly improved sensitivity to dacarbazine in melanoma cells.
Conclusion: These data provide insights into what drives melanoma cells to survive after chemotherapy treatment, thus pointing to strategies for developing combined drug therapies for combating the problem of chemotherapy resistance in melanoma.
Keywords: Melanoma, CXCR1, CXCR2, resistance, chemotherapy, NF-κB.
Current Molecular Medicine
Title:CXCR1/2 Chemokine Network Regulates Melanoma Resistance to Chemotherapies Mediated by NF-κB
Volume: 17 Issue: 6
Author(s): S. Wu, S. Saxena, M.L. Varney and R.K. Singh*
Affiliation:
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5900,United States
Keywords: Melanoma, CXCR1, CXCR2, resistance, chemotherapy, NF-κB.
Abstract: Background: Cancer-related inflammation is recognized as a driver for tumor progression and chemokines are important players in both inflammation and the progression of many cancer types. CXC chemokines, especially CXCL8, have been implicated in melanoma growth and metastasis, while less is known for their roles in drug resistance.
Methods: We generated drug-resistant cells by continuous exposure to chemotherapeutic drugs and analyzed the mechanism(s) of therapy resistance in malignant melanoma.
Results: We report chemotherapies induced upregulation of a variety of chemokines in the CXCR1/CXCR2 network by an NF-κB-dependent mechanism. Notably, analysis of the drug-resistant melanoma cell line selected after prolonged exposure to chemotherapeutic drug dacarbazine revealed higher levels of CXCL8 and CXCR2 compared with parent cells as a signature of drug resistance. CXCR2 neutralization markedly improved sensitivity to dacarbazine in melanoma cells.
Conclusion: These data provide insights into what drives melanoma cells to survive after chemotherapy treatment, thus pointing to strategies for developing combined drug therapies for combating the problem of chemotherapy resistance in melanoma.
Export Options
About this article
Cite this article as:
Wu S. , Saxena S., Varney M.L. and Singh R.K.*, CXCR1/2 Chemokine Network Regulates Melanoma Resistance to Chemotherapies Mediated by NF-κB, Current Molecular Medicine 2017; 17(6) . https://dx.doi.org/10.2174/1566524018666171219100158
DOI https://dx.doi.org/10.2174/1566524018666171219100158 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Novel Methods for the Non-Invasive Administration of DNA Therapeutics and Vaccines
Current Drug Delivery Immune Response to Helper Dependent Adenoviral Mediated Liver Gene Therapy: Challenges and Prospects
Current Gene Therapy Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
Current Cancer Drug Targets Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Modulation of Hepatic MRP3/ABCC3 by Xenobiotics and Pathophysiological Conditions: Role in Drug Pharmacokinetics
Current Medicinal Chemistry Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer
Current Cancer Drug Targets Current Non-viral siRNA Delivery Systems as a Promising Treatment of Skin Diseases
Current Pharmaceutical Design Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Mammary Development and Breast Cancer: The Role of Stem Cells
Current Molecular Medicine Next-Generation Anticancer Metallodrugs
Current Topics in Medicinal Chemistry Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Predicting Chemotherapy Sensitivity Profiles for Breast Cancer Cell Lines with and Without Stem Cell-Like Features
Current Signal Transduction Therapy Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Tumor Cell-Based Vaccination in Renal Cell Carcinoma: Rationale,Approaches, and Recent Clinical Development
Current Drug Targets QSAR Studies on Blood-Brain Barrier Permeation
Current Computer-Aided Drug Design Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry